Loading clinical trials...

NOT_YET_RECRUITINGPHASE2

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer: a Single-center, Randomized Trial

NCT06648200•Shanghai Pulmonary Hospital, Shanghai, China

View on ClinicalTrials.gov

Summary

For extensive-stage small cell lung cancer (SCLC), platinum-chemotherapy (cisplatin or carboplatin) combined with etoposide as the first-line treatment is recommended. However, the recurrence rate is extremely high after the initial first-line treatment. For those who relapse or progress within more than six minths after the end of the-first-line treatment, chose the current guideline recommendation trearment plan has the poor prognosis. A new immunotherapeutic strategy is needed to achieve better anti-tumor effects. JS004 is a new antibody targeting B and T lymphocyte attenuator (BTLA), which restrains immune cells; function and leads to immune escape of tumor cells. The combination of PD-1 and BTLA antibodies has shown a good therapeutic effect in solid tumors. This trial aims to investigate the efficacy and safety of the therapeutic regimen of toripalimab and JS004 combined with platinum-based doublet chemotherapy in extensive-stage SCLC or relapsed within more than six months after radical treatment SCLC.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The patient shall sign the Informed Consent Form;
•2. Aged 18 ≥ years;
•3. Histological or cytological diagnosis of SCLC by needle biopsy or EBUS, and extensive stage or recurrent confirmed by imageological examinations or relapsed within more than six months after radical treatment SCLC;
•4. Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1;
•5. Life expectancy is at least 12 weeks;
•6. At least 1 measurable lesion according to RECIST 1.1;
•7. Patients with good function of other main organs (liver, kidney, blood system, etc.);
•8. Fertile female patients must voluntarily use effective contraceptives from the start of the trial to within 30 days after its completion, and urine or serum pregnancy test results within 7 days prior to enrollment are negative;
•9. Unsterilized male patients must voluntarily use effective contraception during the trial period and for 30 days after its conclusion.

Exclusion Criteria

•1. Patients with a malignancy other than SCLC within five years prior to the start of this trial;
•2. Participants with any unstable systemic disease (including uncontrolled hypertension, severe arrhythmia, etc.);
•3. With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
•4. Participants who are allergic to the test drug or any auxiliary materials;
•5. Participants with active hepatitis B, hepatitis C or HIV;
•6. Participants with Interstitial lung disease currently;
•7. Pregnant or lactating women;
•8. Any malabsorption;
•9. Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
•10. Other factors that researchers think it is not suitable for enrollment.

Locations (1)

Shanghai Pulmonary Hospital

Shanghai, China

Key Dates

Start Date

November 1, 2024

Primary Completion Date

September 1, 2030

Completion Date

September 1, 2030

Last Updated

October 18, 2024

Enrollment

100

ESTIMATED participants

Conditions

Small Cell Lung Cancer Extensive StageSmall Cell Lung Cancer Recurrent

Interventions

JS004

DRUG

Toripalimab

DRUG

Etoposide

DRUG

Platinum

DRUG

Contacts

Peng Zhang, PhD

CONTACT

02165115006 zhangpeng1121@tongji.edu.cn

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

NCT05745350

Small Cell Lung Cancer Extensive Stage

View study

RECRUITINGPHASE2

Liposomal Irinotecan and Apatinib in ES-SCLC

NCT06749691

Small Cell Lung Cancer Extensive Stage

View study

ACTIVE_NOT_RECRUITINGPHASE1

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Liposomal Irinotecan and Apatinib in ES-SCLC

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer